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Abstract
Background: Management of chronic hepatitis C (CHC) has significantly accelerated in the last few years. Currently,
second generation direct acting antivirals (DAAs) promise clearance of infection in most of patients. Here we
present the results of the first analysis carried out on data of Lazio clinical network for DAAs.
Methods: The study was designed as a multicenter cohort: a) to assess the evolution of treatment during the first
24 months of the activity of the Clinical Network; b) to report overall efficacy of treatments; c) to analyze potential
factors associated with lack of virological response at 12 weeks after therapy (SVR12); d) to evaluate the variation of
ALT at baseline and 12 weeks after therapy in those who achieved SVR12 in comparison to those who did not.
Analyses of efficacy were carried out with multilevel mixed effect logistic regression model. ALT temporal variation
was assessed by mixed effect model mixed models with random intercept at patient’s level and random slope at
the level of the time; i.e. either before or after therapy.
Results: Between 30 December 2014 and 31 December 2016 5279 patients started a DAA treatment; of those, 5127
(in 14 clinical centers) had completed the 12-week follow-up. Overall proportion of SVR12 was 93.41% (N = 4780)
with no heterogeneity between the 14 clinical centers. Interruption as the consequence of severe side effect was
very low (only 23 patients). Unadjusted analysis indicates that proportion of SVR12 significantly changes according
to patient’s baseline characteristics, however after adjusting for potential confounders only adherence to current
guidelines, stage of liver diseases, gender, transplant and HIV status were independently associated with the
response to therapy. Analysis of ALT temporal variation showed that ALT level normalized in most, but not, all
patients who achieved SVR12.
Conclusion: Our study confirmed the extraordinary efficacy of DAAs outside clinical trials. The advantage of DAAs
was particularly significant for those patients who were previously considered as difficult-to-treat and did not have
treatment options before DAAs era. Intervention based on network of select centers and prioritization of patients
according to diseases severity was successful. Further studies are needed to establish whether clearance of HCV
after DAAs therapy can arrest or even revert liver fibrosis in non-cirrhotic patients and/or improve life quality and
expectancy in those who achieve SVR12 with cirrhosis.
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Background
The hepatitis C virus (HCV) has been firstly identified in
1989 as a blood-borne human pathogen [1, 2]. Acute in-
fection with HCV is often asymptomatic, however about
80% of infected people cannot clear the virus and de-
velop chronic infection [3, 4]. It is estimated that chronic
hepatitis C (CHC) kills about 700,000 people each year
at global level [5].
Clinical approach for CHC has gradually improved
over the last 30 years [6]. However, since 2014 manage-
ment of CHC has been re-invented by the introduction
of the direct acting antivirals (DAAs) [7]. Registered
clinical trials showed that the combinations of second
generation DAAs can achieve HCV clearance in most of
HCV infected subjects including difficult-to-treat pa-
tients (e.g. those with cirrhosis, transplant recipients,
therapy experienced patients and HIV co-infected sub-
jects) [8]. These astonishing results have been confirmed
by clinical observational studies [9–12] suggesting that
currently anti-HCV therapy may be see also as a public
health intervention aimed to control, and potentially,
eliminate HCV [1, 7, 13, 14].
For maximizing the impact of new therapy at population
level, many National Health Systems promoting universal
access to care [15], have implemented DAAs into clinical
practices using different strategies tailored on the local epi-
demiology of CHC and on the availability of economic re-
sources. Two main strategies [16] have been proposed: a)
treatment as prevention, targeted to reduce incidence of
new HCV infections; b) prioritization for the stage of the
disease, targeted to minimize CHC associated morbidity
and mortality.
According to the Italian National Policies, since Janu-
ary 2015 the health authority of Lazio (an administrative
Region in central Italy) has implemented a strategy for
the access to DAAs based the on prioritization of pa-
tients with advanced liver diseases, extrahepatic mani-
festation and others severe clinical manifestations.
Here we present the results of the first analysis carried
out on data of Lazio clinical network for DAA.
Methods
Study design and aims
This is a multicenter prospective cohort study enrolling
patients with CHC who receive therapy with second
generation DAAs in Lazio. Here we report the analyses
carried out: A) to describe access to DAAs in the Region
and to assess the resilience of the network to changing
policies and guidelines; B) to assess association between
treatment outcome and patient’s epidemiological and
clinical characteristics; C) to evaluate temporal variation
of ALT level before therapy and 12 weeks after the end
of treatment.
Setting
Lazio is an Italian Region with about 5.6 million inhabi-
tants. About 47% of Lazio inhabitants live in Rome, the
only large city. All other people live in the 347 munici-
palities, mainly towns (median habitants 2674 IQR
1120–7997). The Italian National Health System en-
dorsed scheme for reimbursement of DAAs therapies
based on stage of liver disease. These schemes guaran-
teed free access to DAAs to all subjects with CHC ac-
cording to 7 criteria (five additional criteria to expand
access to DAAs have been recently established) [17].
Until the end of 2016 these criteria prioritized for treat-
ment with DAAs patients with cirrhosis (CHILD A and B)
and/or resected HCC, patients with advanced liver fibrosis
(Metavir F3), transplant recipients, candidates to liver trans-
plant, patients with severe extrahepatic manifestations and
patients with METAVIR F2 liver fibrosis with co-morbidities
(HIV/HBV co-infections, non-viral hepatitis, diabetes, BMI
≥30, hemoglobinopathies and coagulation disorders). To im-
plement the national reimbursement scheme and to guaran-
tee equal access to care, Lazio Regional Health Authority
has centralized DAAs supplies and created a clinical net-
work consisting of 14 selected clinical centers for evaluation
and treatment of patients with CHC. In Lazio, no patient
outside this clinical network could receive DAA therapy
under the national reimbursement scheme.
Participants and follow-up
Patients were eligible for analysis if they received therapy
for CHC in the Lazio and:
A. received for the first time one or more of the
subsequent drugs: sofosbuvir (SOF), simeprevir
(SIM), daclatasvir (DAC), ledipasvir (LED),
ombitasvir+paritaprevir+ritonavir± dasabuvir
(2D/3D);
B. started therapy between 30 December 2014 and 31
December 2016
For each patient, we analyzed the following informa-
tion at:
A. Start of therapy: code of the clinical center; date of
start of therapy; criterion for access to DAA, DAA
regimen; age; gender; HCV RNA; HCV genotype;
body max index (BMI); stage of liver diseases,
HBsAg; anti-HIV Ab; status for previous therapy;
ALT; history of OLT and of HCC;
B. end of therapy: date of end of therapy; life status;
whether therapy was interrupted as consequence of
severe adverse reaction;
C. 12 weeks after the end of therapy: date of data
collection; HCV RNA; life status; ALT.
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Treatment outcome
Treatment was successful if patient was alive and with
undetectable HCV RNA level at 12 weeks after the end
of therapy (sustained virological response at 12 weeks
after therapy; SVR12).
Treatment failed if at 12 weeks after the end of ther-
apy patient either: A) had detectable HCV RNA level; B)
started a new anti-HCV treatment; C) has died.
Data sources and measurement
All data analyzed come from the Lazio Regional Net-
work for DAAs. The network has been operational since
30 December 2014 and it was formally enforced by a Re-
gional Act on 12 February 2015. Patient’s clinical charac-
teristics at enrollment were analyzed as reported by
doctors who evaluated patients for eligibility to national
reimbursements scheme. Detection of HCV RNA in
blood was performed by sensitive quantitative molecular
assays with lower limit of detection as declared by
manufacturer (in all cases ≤15 international units/ml);
HCV genotype was determined by method able to dis-
tinguish between genotype 1a and genotype 1b. ALT
level was quantified with standard laboratory methods
implemented in local clinical centers.
For the purpose of this study we used the 2016 EASL
guidelines [8] for defining 3 groups of quality of treat-
ments: group A, treatments considered as optimal in
2016 EASL guidelines; group B, treatments that were
shorter than recommended and/or did not include all
the recommended drugs/combinations and thus were
considered suboptimal in 2016 EASL guidelines; group
C, treatments that contained all drugs as group A, but
also included additional drug (e.g. ribavirin; RBV) and/or
it were longer than recommended. This rating was
meant for assessing the resilience of the network in the
rapidly changing scenario and not for evaluating the per-
formance of the individual clinical centers.
Statistics
Association between patients’ clinical characteristics and
treatment outcome (SVR12) was analyzed in bivariable
and multivariable mixed effect multilevel logistic
(MEML) regression models with random intercept to
correct for the effect of correlation of data at level of the
clinical centers. Bivariable models were used to estimate
proportions of SVR12, to assess potential heterogeneity
across clinical centers and to estimates unadjusted asso-
ciation between proportion of SVR12 and patient’s clin-
ical features. Multivariable MEML was implemented to
adjust for the effect of potential confounders using all
covariates with p < 0.100 in the bivariable analysis.
Odds-ratio (OR) for failing (i.e. the complement of
SVR12) was used to describe the association between
the risk of treatment failure and patient’s characteristics.
Changes of ALT at baseline and 12 after the end of
therapy was assessed for the four groups of patients (i.e.
non-cirrhotic patients with SVR12; non-cirrhotic pa-
tients without SVR12; cirrhotic patients with SVR12 and
non-cirrhotic patients without SVR12). The estimates
were calculated by a balanced (i.e. all patients had value
of ALT at before and 12 weeks after therapy) linear
mixed effect model with random intercept at the level of
patients and random slope at the level of time. We have
previously validated these model in the analysis of com-
plex clinical datasets [18, 19]. Overall the model in-
cluded ALT level as the unique continuous dependent
variable and 3 independent binary variables i.e.: time (ei-
ther at before therapy or 12 weeks after therapy); clinical
outcome (either SVR12 or failure) and presence of cir-
rhosis before therapy (either yes or no) allowing for full
interaction between them.
All analyses and plots were implemented by STATA
13.1 statistical package.
Results
Figure 1 shows the subsets of population included in the
different analyses.
Access to therapy with new DAA
Between 30 December 2014 and 31 December 2016
5279 patients initiated 5350 DAA treatments in Lazio.
Seventy-one treatments were given as given as second
line-treatment and were excluded from the analysis.
Overall the analysis included all the 5279 patients at the
time of their first treatment with DAAs.
Figure 2 shows the number of patients by the time
when therapy was started and DAA combination used.
Among the 5279 patients who received first line treat-
ment with DAAs, SOF was the most used drug (87.07%;
N = 4438) followed by LED (36.92%; N = 1949) DAC (20.
06%; N = 1059), 2D/3D combinations (14.76%; N = 779)
and SIM (13.71%; N = 724). RBV was used in about half
of all DAA scheme (49.69%; N = 2623) while the use of
pegylated interferon in combination either with SOF (1.
48%; N = 78) or SIM (1.18%; N = 62) plus RBV was mar-
ginal and limited to the earliest period only Treatment
intended duration ranged between 8 and 48 weeks, but
almost all the treatments were planned for a duration of
either 12 (57.81%; N = 3052) or 24 weeks (41.37%; N =
2184). Only few DAA treatments were planned for a
duration of either 8 (0.45% N = 24), 16 (0.08% N = 4) or
48 weeks (0.28% N = 15) (Table 1).
The proportion of patients who received DAA com-
binations consistent with EASL 2016 guidelines was
very low until May 2015 and eventually steadily in-
creased between June 2015 and December 2016 when
the 73.68% of all treatment were consistent with
EASL 2016 guidelines (Fig. 3a). however, the analysis
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of DAA combination according to previous guidelines
suggested that: A) for treatments started under EASL
2014 GL (i.e. by 21st April 2015) none could be classified
as sub-optimal; B) for treatments started under EASL
2015 GL (i.e. after 22nd April 2016) 269 can be classified
as sub optimal, the main reason was under use of ribavirin
in cirrhotic patients in genotype 1 and 3 (N = 221; 82%);
C) for treatments started under EASL 2016 GL (i.e. after
22nd September 2016) 89 can be classified as sub optimal,
the main reason was under use of ribavirin in cirrhotic pa-
tients with genotype 3 (N = 30; 44%) and use of SOF +
RBV in gen 2 (N = 28; 32%).
The proportion of patients who received DAA without
cirrhosis steadily increased over time being none during
Fig. 1 Flow charts to describe selection of population sample included in the different analyses. Blue boxes report the number of patients in
each stage of selection; green boxes report excluded subjects with reason; orange boxes report the type of analysis carried out
Fig. 2 Distribution of the 5279 DAA naïve patients according to DAAs combination and month of start of therapy. SOF: sofosbuvir±ribavirin±Peg-
Interferon; SIM: simeprevir+ribavirin+Peg-interferon. 2D/3D: ombitasvir+paritaprevir+ritonavir±dasabuvir±ribavirin; LED+SOF: ledipasvir+sofobuvir;
DAC + SOF: daclatasvir+sofosbuvir. The frequency of each specific combination is reported in Table 1
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the first 2 months of the study period and 51.05% by De-
cember 2016 (Fig. 3b).
Treatment efficacy at 12 weeks after the end of therapy
The overall proportion of lost to follow-up was 2.88%
(152 out of 5279 patients who started therapy). The
bivariable analysis of efficacy was carried out on the
5127 patients who had completed the follow-up at
12 weeks post treatment. Overall SVR12 proportion was
93.41% (95% CI 92.48–94.34%) with no evidence of het-
erogeneity across clinical centers (p for heterogeneity in
null model = 0.219).
In total 347 (6.59%) patients did not achieve SVR12;
among them, 72 patients died by week 12 post-
treatment (31 of whom during treatment) and only 23
patients interrupted the treatment for drug toxicity.
Table 2 shows descriptive analysis and the results of
bivariable MEML models to assess potential association
between SVR12 and individual patient’s characteristics.
Proportions of SVR12 significantly change according to
all analyzed patients’ baselines characteristics apart from
age and previous history of treatment (range: 76.60–96.
48%; see Table 2). Table 3 shows the results of
Table 1 DAA treatments schemes
Drugs Intended duration Total
12 weeks 24 weeks Other
SIM + SOF 362 – – 362
SIM + SOF + RBV 298 2 – 300
DAC + SOF 403 262 – 665
DAC + SOF + RBV 75 319 – 394
LED + SOF 573 711 24a- 1308
LED + SOF + RBV 425 216 – 641
3D 318 – – 318
3D + RBV 288 66 – 354
2D + RBV 58 49 – 107
SOF + RBV 175 500 15b 690
SIM + PEG + RBV – 58 4c 62
SOF + PEG + RBV 77 1 – 78
Total 3052 2184 43 5279
Number of treatments according to DAAs combination and intended duration
of the therapy. a8 weeks (N = 24); b48 weeks (N = 12) and 16 weeks (N = 3);
c16 weeks (N = 1) and 48 weeks (N = 3)
b
a
Fig. 3 Proportion of the patients according quality of treatment and urgency of treatment. a Monthly proportion of the 5279 patients who
received either sub-optimal, optimal or not recommend of treatment according to EASL 2016 guidelines. Group A, treatments currently considered as
optimal in 2016 EASL guidelines; group B, treatments that is shorter than currently recommended and/or does not included all the recommended
drugs/combinations and thus considered suboptimal in 2016 EASL guidelines; group C, treatments that contains all drugs as group A, but also included
additional drug (e.g. ribavirin RBV) and/or it is longer than currently recommended. NA: not assessable (patients’ information to assess quality are
missing). b Monthly proportion of the 5279 patients who had access to therapy by base line clinical features. Urgent:: patients with cirrhosis, candidate
to liver transplant; recipients of organ transplant, patients with severe HCV associated extra-hepatic manifestation; Non cirrhotic: all other patients
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Table 2 Descriptive analysis and the results of bivariable MEML models for efficacy
Patient’s clinical features Descriptive SVR (%) P-value
Fail SVR12 TOT estimate 95% CI
Total 347 4780 5127 93.41% 92.48% 94.34% NA
Treatment group group B 182 1488 1670 89.50% 87.66% 91.34% < 0.001
group A 72 1891 1963 96.48% 95.58% 97.38%
group C 84 1357 1441 94.43% 93.09% 95.77%
NA 9 44 53 – – – –
Cirrhosis no 81 1937 2018 95.99% 95.13% 96.84% < 0.001
CHILD A 194 2606 2800 93.07% 92.13% 94.01%
CHILD B/C 72 237 309 76.70% 71.99% 81.41%
NA 0 0 0 – – – –
Sex female 85 1848 1933 95.67% 94.70% 96.65% < 0.001
male 262 2932 3191 91.98% 90.77% 93.18%
NA 0 0 0 – – – –
Age ≤59 194 2474 2668 92.96% 91.73% 94.19% 0.141
≥60 150 2281 2431 93.98% 92.88% 95.08%
NA 3 25 28 – – – –
BMI BMI < 30 288 4080 4368 93.57% 92.62% 94.53% 0.176
BMI≥ 30 59 683 742 92.25% 90.21% 94.29%
NA 0 17 17 – – – –
HCV RNA a T0 (Log10 UI/L) ≤ 5.99 206 2455 2661 92.39% 91.15% 93.62% 0.005
≥6.00 140 2306 2446 94.34% 93.33% 95.35%
NA 1 19 20 – – – –
Genotype 1a 81 1102 1183 93.30% 91.73% 94.88% 0.011
1b 119 1866 1985 94.09% 92.95% 95.24%
2 39 679 718 94.64% 92.94% 96.33%
3 77 728 805 90.64% 88.43% 92.84%
4 30 401 431 93.18% 90.72% 95.63%
NA 1 4 5 – – – –
Previous therapy naive 191 2599 2790 93.49% 92.27% 94.71% 0.758
experienced 132 1876 2008 93.71% 92.41% 95.01%
NA 24 305 329 – – – –
OLT no 330 4662 4992 93.53% 92.63% 94.42% 0.009
yes 17 118 135 87.75% 82.11% 93.39%
NA 0 0 0 – – – –
HIV HIV neg. 285 4082 4367 93.65% 92.67% 94.62% 0.014
HIV pos. 55 527 582 90.89% 88.28% 93.50%
NA 7 171 178 – – – –
HCC No 324 4626 4950 93.70% 92.73% 94.67% < 0.001
yes 20 94 114 82.80% 75.73% 89.87%
NA 3 60 63 – – – –
Descriptive and unadjusted analysis reporting the distribution of patient’s characteristics according to SVR12. 95% CI and P-values are calculated according
multivariable mixed effect logistic model which take into account variability due to data correlation at 14 clinical centers. BMI body max index, OLT orthotopic
liver transplant, HCC hepatocellular carcinoma, NA not available
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multivariable MEML model to adjust for potential con-
founding bias. This model showed that after adjusting
for other co-variates the treatment group (p < 0.001),
stage of liver diseases (p < 0.001), gender (p < 0.001),
OLT (p = 0.005) and HIV serostatus (p = 0.019) where
significantly associated with SVR12. In addition, no
heterogeneity for efficacy across clinical centers was
observed (p for heterogeneity in multivariable
MEML = 1.000).
Temporal variation of ALT level before therapy and at
12 weeks after the end of treatment
Figure 4 shows the temporal variation of ALT level be-
fore therapy and 12 weeks after the end of treatment in
the four different classes of patients; i.e.: patients with
cirrhosis who did not achieve SVR12; patients with cir-
rhosis who achieved SVR12; patients without cirrhosis
who did not achieve SVR12; patients without cirrhosis
who achieved SVR12. This analysis was carried out on a
convenient sample of 3179 subjects who had ALT
determination both before start of therapy and at the
end of the follow-up.
Figure 4a shows the distribution of ALT levels for the
3179 patients included in the analysis (overall 6358 ALT
determinations). ALT levels were above the upper normal
limit (40 U/L) in more than 75% of patients before treat-
ment (blue boxes in Fig. 4a). In contrast, at 12 weeks after
therapy, ALT levels normalized in more than 75% of pa-
tients with SVR12 and in about 50% of those who failed,
regardless the stage of liver diseases, (red boxes in Fig. 4a).
Average reduction of ALT levels before therapy and
12 weeks after therapy, 95% CI and p-value according to
stage of liver diseases (i.e. either with or without cirrhosis)
and outcome of therapy (i.e.: either SVR12 or fail) are re-
ported in Fig. 4b. This analysis provides strong evidence
that ALT significantly decreased in all patients. However,
the degree of reduction was more than 2 times higher in
those who achieved SVR12 than in those who did not.
Discussion
To our knowledge, this is one of the largest prospective
observational study carried out using real clinical data of
patients treated with second generation DAAs. Real world
studies like this are pivotal to assess the actual impact of
new therapies on real clinical practice and to confirm effi-
cacy and safety of new drugs outside clinical trials.
We showed that Lazio clinical network was capable of
timely dealing with the changing guidelines and the on-
going process of approval drug. Newly DAAs were in-
cluded in treatment with no delay, besides, the
adherence to current standard of care steadily increased
over time following to the publication of new guidelines.
In addition, the number of patients who started therapy
with cirrhosis steadily decreased over time, suggesting
that the patients with advanced liver disease and repli-
cating HCV infection have been steadily decreasing. For
these reasons, since April 2017 the Italian policies for re-
imbursement of DAAs have been extended to include
several sub-groups of patients in addition to those with
urgent need of therapy [17].
We found that overall efficacy of DAAs therapies was
well above 90% (i.e.: 93.41% with a 95% CI between 92.
48 and 94.34%) which is within the efficacy range re-
ported in clinical trials [20]. A large real world clinical
study carried out in USA enrolling 4365 patients with
HCV genotype 1 infection reported slightly lower effi-
cacy rate with SVR12 between 91.3 and 92.0% [21]. This
marginal difference could be due to differences in base-
line characteristics; the USA study includes only geno-
type 1 and about 36.5% of African-American patients, in
whom SVR12 rates were significantly lower than in
European ones (89.8% vs. 92.8%). In addition, better pro-
portion of SVR12 in our study compared to the USA co-
hort may be due to different patient management, as
Table 3 Multivariable MEML model for efficacy
Patients’ clinical features Odds ratio for failure P-value
estimate 95% CI
Treatment group group B 2.62 1.91 3.58 < 0.001
group A Base – –
group C 1.23 0.85 1.77
Cirrhosis no Base – – < 0.001
CHILD A 1.56 1.15 2.11
CHILD B/C 5.39 3.64 7.98
Sex female Base – – < 0.001
male 1.84 1.40 2.43
HCV RNA a T0 (Log10 UI/L) ≤ 5.99 Base – – 0.173
≥6.00 0.84 0.66 1.08
Genotype 1a 1.38 0.89 2.14 0.252
1b 1.44 0.96 2.16
2 Base – –
3 1.61 1.05 2.48
4 1.48 0.86 2.57
OLT no Base – – 0.005
yes 2.26 1.27 4.01
HIV HIV neg. Base – – 0.019
HIV pos. 1.48 1.07 2.06
HCC no Base – – 0.085
yes 1.61 0.94 2.76
Multivariable mixed effect logistic model to assess association of failing to
achieve SVR12 after adjusting for potential confounders. The model has been
set by including patients’ characteristics with p-value < 0.100 at unadjusted
analysis (Table 2). 95% CI and P-values are calculated according considering
variability due to data correlation at 14 clinical centers. OLT orthotopic liver
transplant, HCC hepatocellular carcinoma
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acknowledged by Calleja et al. [22] Indeed, multicenter
prospective cohort studies carried out in other European
settings, such as Spain [23] and Germany [24, 25], re-
ported proportions of SVR similar to those observed in
our study. In our clinical network, patients were man-
aged by experienced clinicians in selected clinical centers
rather than in community-based practice, which may
have resulted in better adherence to treatment and con-
sequently higher SVR12 rate [26]. The circumstance that
our patients received homogeneously high quality of
care throughout the Region was confirmed by no hetero-
geneity of efficacy across clinical centers and the very
low level of lost to follow-up.(2.88%) Indeed, lost to
follow-up proportion was more than 2 times lower than
that reported in USA (6.80%) and comparable to those
observed in similar clinical setting in Spain (2.71%) [23]
and Germany (4.89%) [24].
After adjusting for other confounders, we found that
quality of treatment, stage of liver diseases, gender, OLT
and HIV serostatus were independent predictors of SVR12.
Our study includes a considerable number of patients
who received a quality of treatment currently considered
as either sub-optimal (group B) or not recommended
(group C) [8]. This mirrors the dynamic real-world sce-
nario analyzed, where standard of care changed accord-
ing to the availability of additional DAAs and new
clinical recommendations. In Italy SOF became reim-
bursable from December 2014, SIM from February 2015,
DAC from April 2015 and SOF + LDV, 2D and 3D from
May 2015. When the clinical network was established,
effective EASL guidelines were those available since May
2014 [27] which were updated on April 2015 [28] and
eventually on September 2016 [8]. As in other prospect-
ive studies carried out in Italy [10], our study provided
strong evidence that adherence to the most current stan-
dards of care was associated with higher proportions of
SVR12 than receiving DAAs combinations which were
eventually considered sub-optimal. In addition, we did
not find significant association between failure and not
recommended, though not suboptimal, treatments, as
those included in group C.
Cirrhosis remains a significant challenge in the DAAs
era. Although, the observed efficacy of DAA therapies
was much higher than that expected for interferon plus
ribavirin therapies [6], unadjusted analysis showed that
SVR12 dropped from 95.99% in patients without cirrho-
sis to 76.70% in those with decompensated cirrhosis.
Multivariable analysis confirmed this observation and
provided evidence that, in comparison with patients
without cirrhosis, the risk of failing SVR12 was 1.56 and
5.39 times higher in patients with either compensate or
decompensate cirrhosis, respectively. Unadjusted propor-
tions of SVR12 in patients with cirrhosis were slightly lower
in our population than those estimated in other studies
where patients with cirrhosis received SOF in combination
with either DAC [29–31] or LED [30–32]. The difference
may be due to the unavailability of such regimens in the
earliest period of the study, when SOF in combination with
RBV was the only available combination.
We found that females exhibited higher proportion of
SVR12 than males. The role of gender as predictor of re-
sponse to anti-HCV therapies has been debated since
long before DAAs introduction. Population studies pro-
vided evidence that females were more likely than males
a b
Fig. 4 Kinetics of ALT level in 4 different groups of patients according to the stage of liver disease (i.e. with/without cirrhosis) and therapy
outcome (i.e. fail or SVR12). a Box-plot describe the distribution of the 3179 patients according values of ALT level patients either before the start
of therapy (blue boxes; T0) and eventually 12 weeks after therapy (red boxes; FUP12). Almost all patients had ALT value above upper normal limit
(black dotted line; 40 U/L) before therapy. More than 75% of patients who achieve SVR12 normalized ALT at 12 weeks after the end of therapy. A
normalization of ALT values was also reported in about 50% of those who did not achieve SVR at 12 weeks after the end of therapy. b Temporal
variation of ALT levels before treatment and 12 weeks after the endo of therapy. Estimates, 95%CI and p-values were carried out according to a
mixed effect model which take in account correlation of data at the level of each individual patients. A significant reduction of ALT is reported
for all patients. However average reduction of ALT levels is about 2 time higher in those who achieved SVR12 than in those who did not
Lanini et al. BMC Infectious Diseases  (2018) 18:223 Page 8 of 12
to naturally clear HCV after infection [33]. Clinical
studies suggested that young females had better re-
sponse to interferon therapy than males [34–36] but
menopause may abolish this advantage [37]. Recent clin-
ical experiences with DAAs seem to confirm this obser-
vation [24, 38], however whether a causal (biological)
link stands behind the association between gender and
response to anti HCV therapies is unclear, yet. The ex-
planation of the potential biological pathways of the as-
sociation between SVR12 and gender is beyond the
scope of this study. Nevertheless, it is worth of notice
that our estimate (OR 1.84 95% CI 1.40–2.43) is widely
consistent with those reported in similar large prospect-
ive studies carried out in Europe [23, 24, 39, 40].
We found that HIV serostatus was an independent
predictor of SVR12. The potential effect of HIV serosta-
tus on efficacy of new DAAs therapies is currently de-
bated. Bischoff et al. [39] found that HIV positive and
HIV negative subjects had similar proportion of SVR12
(90.3 and 91.2%, respectively). However, these results
may be the consequence of confounding as prevalence
of cirrhosis was significantly higher among HIV negative
than among HIV positive subjects (29.5% vs 17.2%, re-
spectively; p < 0.001) and authors did not adjust statistics
for the level of liver diseases in the multivariable ana-
lysis. In contrast, Neukam et al. [41], reported that, after
adjustment for potential confounders, including cirrho-
sis, HIV positivity was associated with lower proportion
of SVR12. Moreover, recent studies specifically focused
on HIV positive population reported proportions of SVR
consistent to those observed in our study and emphasize
that level of CD4 is directly associated with SVR12 [40].
Consistently with these latter experiences our study sug-
gests that, even if DAAs are very effective in HIV posi-
tive subjects (with SVR12 portion higher than 90%),
patient with HIV may still have marginally lower propor-
tion of SVR12 than those without HIV infection.
We found a proportion of SVR among OLT recipients
of 87.75% (95 82.11–93.39%) which is significantly lower
than SVR in subjects without OLT. This is one of the
first large prospective study which attempted to assess
association between OLT and SVR. Our observation is
consistent with punctual estimates of SVR proportion
reported in prospective studies enrolling OLT patients
only [42, 43].
Finally, our study provided strong evidence that DAAs
therapy was associated with a significant reduction of
liver cytolysis. The role of DAAs in the reduction of liver
damage has been already suggested by a previous study
[44]. However, we found that ALT levels normalized in
most, but not all, patients who achieved SVR12, imply-
ing that hepatic inflammation may continue in a sub set
of patients despite HCV clearance [45]. This finding also
suggest that patients who achieved SVR12 would need
long-term clinical follow-up to monitor the improve-
ment of liver diseases and further underlines that HCV
infection may be associated with comorbidities that on
one hand contribute to the progression of the disease
and, on the other hand, need to be managed once HCV
has been eradicated.
Limitation of our study are related to: A) observational
design, thus confounding due to unmeasured exposures
cannot be ruled out; B) even though the information
were collected through a compulsory system enforced by
Regional laws, we still had a moderate proportion of
missing data; C) analysis to assess the effect of SVR on
hepatic cytolysis was carried out on convenient sub set
of patient for whom ALT determinations were available;
D) we do not systematically collect data on resistance
before therapy, this limitation may be marginal for the
purposes of our analyses as current guidelines does not
recommend resistance testing prior to treatment with
DAAs and acknowledge that treatment regimens can be
optimized without this information [8].
Conclusion
In conclusion, our study confirmed the extraordinary effi-
cacy of DAA therapies outside clinical trials and provided
evidence that adherence to most current guidelines can fur-
ther improve the response rate in all patients. The advan-
tage of using DAAs was particularly significant for those
patients who were previously considered as difficult-to-
treat and had no-treatment option before DAAs era. As in
other European experiences, our model of intervention
based on the creation of a network of select clinical centers
and prioritization of patients according to diseases severity
was successful and guaranteed timely implementation of
new drug combinations, high level of SVR12 and the sig-
nificant reduction of patients with advance stage CHC in
urgent need of therapy. Our study analyzed as the only out-
come clearance of HCV infection (i.e. SVR12) thus it pro-
vides no information about the actual impact of DAAs
therapy on patient’s life quality and expectancy after SVR.
Further studies are needed to establish whether clearance
of HCV after DAAs therapy can arrest, or even revert, liver
fibrosis in non-cirrhotic patients and/or improve life ex-
pectancy in those who achieved SVR12 with advanced stage
live disease [46]. In our opinion, long term clinical follow-
up is needed also in patients who achieved SVR12.
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